Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes

References

• . Théroux P, Lidón R. Unstable angina: pathogenesis, diagnosis, and treatment. Curr Probl Cardiol. 1993;18(3):157–231
   PubMed Web of Science ®Google Scholar
• . Chesebro JH, Fuster V. Thrombosis in unstable angina. N Engl J Med. 1992;327(3):192–194
   PubMed Web of Science ®Google Scholar
• . Rizik D, Healy S, Margulis A, . A new clinical classification for hospital prognosis of unstable angina pectoris. Am J Cardiol. 1995;75(15):993–997
   PubMedGoogle Scholar
• . Braunwald E, Antman EM, Beasley JW, . ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation. 2000;102(10):1193–1209
   PubMed Web of Science ®Google Scholar
• . Hardisty RM, Powling MJ, Nokes TJ. The action of ticlopidine on human platelets. Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost. 1990;64(1):145–150
   PubMedGoogle Scholar
• . Lewis HD Jr, Davis JW, Archibald DG, . Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309(7):396–403
   PubMed Web of Science ®Google Scholar
• . Cairns JA, Gent M, Singer J, . Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med. 1985;313(22):1369–1375
   PubMed Web of Science ®Google Scholar
• . Théroux P, Ouimet H, McCans J, . Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319(17):1105–1111
   PubMed Web of Science ®Google Scholar
• . Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol. 1991;18(7):1587–1593
   PubMedGoogle Scholar
• . Borzak S, Cannon CP, Kraft PL, . Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. TIMI 7 Investigators. Thrombin Inhibition in Myocardial Ischemia. Am J Cardiol. 1998;81(6):678–681
   PubMedGoogle Scholar
• . Alexander JH, Harrington RA, Tuttle RH, . Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrum Therapy. Am J Cardiol. 1999;83(8):1147–1151
   PubMedGoogle Scholar
• . Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86
   PubMed Web of Science ®Google Scholar
• . Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988;2(8607):349–360
   PubMedGoogle Scholar
• . Wright RS, Anderson JL, Adams CD, . 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57(19):1920–1959
   PubMedGoogle Scholar
• . Ibáñez L, Vidal X, Vendrell L, Moretti U, Laporte JR; Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23(2):235–242
   PubMedGoogle Scholar
• . Hollopeter G, Jantzen HM, Vincent D, . Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202–207
   PubMed Web of Science ®Google Scholar
• . Savi P, Pereillo JM, Uzabiaga MF, . Identification and biological activity of the active metabolite of Clopidogrel. Thromb Haemost. 2000;84(5):891–896
   PubMed Web of Science ®Google Scholar
• . Balsano F, Rizzon P, Violi F, . Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell' Angina Instabile Group. Circulation. 1990;82(1):17–26
   PubMedGoogle Scholar
• . Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in addition to aspirin inpatients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502
   PubMed Web of Science ®Google Scholar
• . Peters RJ, Mehta SR, Fox KA, ; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with Clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108(14):1682–1687
   PubMed Web of Science ®Google Scholar
• . Budaj A, Yusuf S, Mehta SR, ; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of Clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106(13):1622–1626
   PubMed Web of Science ®Google Scholar
• . Mehta SR, Yusuf S, Peters RJ, ; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of pretreatment with Clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533
   PubMed Web of Science ®Google Scholar
• . Steinhubl SR, Berger PB, Mann JT 3rd, ; CREDO Investigators; Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420
   PubMed Web of Science ®Google Scholar
• . Mehta SR, Bassand JP, Chrolavicius S, ; CURRENT-OASIS 7 Investigators. Dose comparisons of Clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363(10):930–942
   PubMed Web of Science ®Google Scholar
• . Pierre—Louis B, Aronow WS, Yoon JH, . Risk factors for major bleeding and for minor bleeding after percutaneous coronary intervention in 634 consecutive patients with acute coronary syndromes. Am J Ther. 2010;17(4):e74–e77
   Google Scholar
• . Feldman DN, Fakorede F, Minutello RM, Bergman G, Moussa I, Wong SC. Efficacy of high-dose Clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol. 2010;105(3):323–332
   PubMed Web of Science ®Google Scholar
• . Paré G, Mehta SR, Yusuf S, . Effects of CYP2C19 genotype on outcomes of Clopidogrel treatment. N Engl J Med. 2010;363(18):1704–1714
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Trenk D, Frelinger AL, ; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose Clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923–2932
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Investigators. Prasugrel versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, McCabe CH, ; TRITON-TIMI 38 Invesitgators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353–1363
   PubMed Web of Science ®Google Scholar
• . Wiviott SD, Braunwald E, Angiolillo DJ, ; TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–1636
   PubMed Web of Science ®Google Scholar
• . Fuster V, Farkouh ME. Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel [editorial]. Circulation. 2008;118(16):1607–1608
   PubMedGoogle Scholar
• . O'Donoghue ML, Braunwald E, Antman EM, . Pharmacodynamic effect and clinical efficacy of Clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374(9694):989–997
   PubMed Web of Science ®Google Scholar
• . Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to Clopidogrel with aspirin. Eur Heart J. 2006;27(9):1038–1047
   PubMed Web of Science ®Google Scholar
• . Nawarskas JJ, Clark SM. Ticagrelor: a novel reversible oral antiplatelet agent. Cardiol Rev. 2011;19(2):95–100
   PubMedGoogle Scholar
• . Gurbel PA, Bliden KP, Butler K, . Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus Clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–2585
   PubMed Web of Science ®Google Scholar
• . Wallentin L, Becker RC, Budaj A, ; PLATO Investigators. Ticagrelor versus Clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057
   PubMed Web of Science ®Google Scholar
• . Armstrong PW, Siha H, Fu Y, . ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation. 2012;125(3):514–521
   PubMedGoogle Scholar
• . Gaglia MA Jr, Waksman R. Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor. Circulation. 2011;123(4):451–456
   PubMedGoogle Scholar
• . Cannon CP, Harrington RA, James S, ; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with Clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–293
   PubMed Web of Science ®Google Scholar
• . Held C, Asenblad N, Bassand JP, . Ticagrelor versus Clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57(6):672–684
   PubMed Web of Science ®Google Scholar
• . James S, Budaj A, Aylward P, . Ticagrelor versus Clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056–1067
   PubMed Web of Science ®Google Scholar
• . Gurbel PA, Bliden KP, Butler K, . Response to ticagrelor in Clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–1199
   PubMed Web of Science ®Google Scholar
• . Boersma E, Harrington RA, Moliterno DJ, . Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359(9302):189–198
   PubMed Web of Science ®Google Scholar
• . Giugliano RP, White JA, Bode C, ; EARLY ACS Investigators. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med. 2009;360(21):2176–2190
   PubMed Web of Science ®Google Scholar
• . Stone GW, Bertrand ME, Moses JW, ; ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. JAMA. 2007;297(6):591–602
   PubMed Web of Science ®Google Scholar
• . Harrington RA, Stone GW, McNulty S, . Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009;361(24):2318–2329
   PubMed Web of Science ®Google Scholar
• . Bhatt DL, Lincoff AM, Gibson CM, ; CHAMPION PLATFORM Investigators. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med. 2009;361(24):2330–2341
   PubMed Web of Science ®Google Scholar
• . Tricoci P, Huang Z, Held C, ; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366(1):20–33
   PubMed Web of Science ®Google Scholar
• . Peters RJ, Mehta SR, Fox KA, ; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with Clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108(14):1682–1687
   PubMed Web of Science ®Google Scholar